A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer

PURPOSE: Aurora Kinase A (AKA) inhibition with gemcitabine represents a potentially synergistic cancer treatment strategy via mitotic catastrophe. The feasibility, safety, and preliminary efficacy of alisertib (MLN8237), an oral AKA inhibitor, with gemcitabine was evaluated in this open-label phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Justin A., Huynh, Jasmine C., Wu, Chun-Yi, Yu, Ai-Ming, Matsukuma, Karen, Semrad, Thomas J., Gandara, David R., Li, Tianhong, Riess, Jonathan W., Tam, Kit, Mack, Philip C., Martinez, Anthony, Mahaffey, Nichole, Kelly, Karen L., Kim, Edward J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402746/
https://www.ncbi.nlm.nih.gov/pubmed/35907014
http://dx.doi.org/10.1007/s00280-022-04457-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402746/
https://www.ncbi.nlm.nih.gov/pubmed/35907014
http://dx.doi.org/10.1007/s00280-022-04457-9

Ejemplares similares